Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Insmed ( (INSM) ).
On May 15, 2025, Insmed Incorporated, a company in the healthcare industry, held its annual meeting where shareholders approved several key proposals. These included the election of Class I directors, an advisory vote on executive compensation, the ratification of Ernst & Young LLP as the independent accounting firm, and the approval of Amendment No. 2 to the 2019 Incentive Plan. The approval of these proposals, particularly the amendment to the incentive plan, is expected to impact the company’s strategic direction and governance, reflecting shareholder support for the company’s leadership and future initiatives.
The most recent analyst rating on (INSM) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.
Spark’s Take on INSM Stock
According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.
Insmed’s stock score reflects the company’s challenging financial performance, with consistent losses and high leverage posing significant risks. Technical analysis indicates bearish momentum, while the negative P/E ratio suggests caution in valuation. Positives from the earnings call, including strong cash reserves and progress in clinical programs, along with favorable corporate events, provide some optimism but are overshadowed by financial and market challenges.
To see Spark’s full report on INSM stock, click here.
More about Insmed
Average Trading Volume: 2,256,631
Technical Sentiment Signal: Buy
Current Market Cap: $11.95B
Learn more about INSM stock on TipRanks’ Stock Analysis page.